| Literature DB >> 27927007 |
Chan-Mi Park1,2, Hye-Min Kim1,3, Dong Hyun Kim1,3, Ho-Jin Han1,3, Haneul Noh1, Jae-Hyuk Jang1,3, Soo-Hyun Park4, Han-Jung Chae4, Soo-Wan Chae4, Eun Kyoung Ryu5, Sangku Lee1, Kangdong Liu1, Haidan Liu1, Jong-Seog Ahn1,3, Young Ock Kim6, Bo-Yeon Kim1,3, Nak-Kyun Soung1,3.
Abstract
Ginsenosides, which are the active materials of ginseng, have biological functions that include anti-osteoporotic effects. Aqueous ginseng extract inhibits osteoclast differentiation induced by receptor activator of NF-κB ligand (RANKL). Aqueous ginseng extract produces chromatography peaks characteristic of ginsenosides. Among these peaks, ginsenoside Re is a major component. However, the preventive effects of ginsenoside Re against osteoclast differentiation are not known. We studied the effect of ginsenoside Re on osteoclast differentiation, RANKL-induced tartrate-resistant acid phosphatase (TRAP) activity, and formation of multinucleated osteoclasts in vitro. Ginsenoside Re hampered osteoclast differentiation in a dose-dependent manner. In an in vivo zebrafish model, aqueous ginseng extract and ginsenoside Re had anti-osteoclastogenesis effects. These findings suggest that both aqueous ginseng extract and ginsenoside Re prevent bone resorption by inhibiting osteoclast differentiation. Ginsenoside Re could be important for promoting bone health.Entities:
Keywords: RANKL; ginsenoside Re; osteoclasts; zebrafish
Mesh:
Substances:
Year: 2016 PMID: 27927007 PMCID: PMC5223102 DOI: 10.14348/molcells.2016.0111
Source DB: PubMed Journal: Mol Cells ISSN: 1016-8478 Impact factor: 5.034
Fig. 1Aqueous ginseng extract inhibition of osteoclast differentiation, and effects of 14 ginsenosides on osteoclast differentiation. (A) Mouse BMMs were harvested and exposed for 3 days to RANKL (25 ng/ml) and M-CSF (10 ng/ml) with or without ginseng active compounds. TRAP staining was performed, and (B) TRAP activity was measured at λ = 405 nm. Data are expressed as the percentage of TRAP activity in ginseng extract treated cells compared to untreated cells (mean ± SEM, n = 3) in blue, with cell viability at the same ginseng concentration tested by MTT assay in red. (C) RANKL-induced BMMs were treated with 14 ginsenosides, and osteoclast differentiation was evaluated by TRAP activity measured at λ = 405 nm. Data are expressed as a percentage of TRAP activity of untreated cells (mean ± SEM, n = 3). The red line indicates 60% inhibition at 2.5 μM. More effective ginsenosides are indicated in red. (d) Summary of osteoclast-differentiation inhibition efficiency of 14 ginsenosides and cell viability by MTT assays. EC50, half-maximal effective concentration. IC50, half-maximal growth inhibition concentration. Scale bar, 100 μm.
Fig. 2Effect of aqueous ginseng extract on osteoporosis in the zebrafish scale model. (A) After treatment with aqueous ginseng extract (GE, 10 μg/ml) for 35 days, zebrafish were scanned by μ-CT to visualize vertebrae density. (B) Calcium/phosphorous ratios were measured in vertebrae and scales from zebrafish samples by inductively coupled plasma mass spectrometry. (C) RT-PCR was performed to determine the mRNA expression levels of osteoclast marker genes TRAP, MMP9, and MMP2 of and β-actin. (D) Zebrafish scales were stained with TRAP. Scale bar, 100 μm.
Fig. 3Effect of ginsenoside Re on osteoclast differentiation. (A) Total osteoclast formation by BMMs treated with the indicated concentrations of ginsenoside Re. TRAP staining was performed after 3 days to show TRAP + multinucleated cells, which were rare in the concentration of 5 μM groups. 40x. (B) TRAP activity was measured at λ = 405 nm. Data are expressed as a percentage of the TRAP activity of untreated cells (means ± SEM, n = 3). (C) TRAP-positive cells were counted under the same conditions. (D, E) qPCR was performed to confirm the mRNA expression levels of NFATc1 and TRAP genes. (F) Cell viability at the indicated concentration of ginsenoside Re was tested by MTT assay.
Fig. 4Inhibition of ERK and NF-κB pathways by ginsenoside Re in BMMs. (A) BMMs were treated with ginsenoside Re (0–10 μM) with M-CSF (30 ng/ml) and RANKL (25 ng/ml) for 2.5 days. Whole cell lysates were extracted for Western blotting using antibodies against NFATc1, c-Fos, and CYLD. (B, F) BMMs were treated with ginsenoside Re (10 μM) or control (DMSO) for the indicated times. Whole cell lysates were used for Western blotting with antibodies against p-ERK, ERK, p-p38, p38, p-JNK, JNK, p-IκBα, and IκBα. GAPDH was the reference protein. (C, D, E, and G) The intensities of p-ERK, p-p38, p-JNK and p- IκBα were measured by densitometer. *P < 0.05 by one-way ANOVA.
Fig. 5Effect of ginsenoside Re on zebrafish scale osteoclasts. (A) Ginsenoside Re-treated zebrafish scales were stained with TRAP. Red box, magnified X200; arrow, TRAP-positive signal. (B) TRAP signal intensity was measured in lateral regions. Five randomly selected points were measured per treated scale. (C, D) qPCR was performed to determine the mRNA levels of the osteoclast markers TRAP and cathepsin K and (E, F) the osteoblasts markers ALP and osterix.*P < 0.05 and **P < 0.01 by student’s t-test.